Novocure’s pancreatic cancer treatment meets main goal in late-stage study

Novocure (NVCR.O) said on Monday its experimental therapy extended the lives of patients with a form of advanced pancreatic cancer when combined with chemotherapy, achieving the primary goal in a late-stage trial.